Linked Life Data

20679180

Source:http://linkedlifedata.com/resource/pubmed/id/20679180

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-9-16
pubmed:abstractText
3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are effective in the primary and secondary prevention of cardiovascular events. Although originally developed to improve lipid profile, statins have demonstrated a surplus of beneficial pleiotropic effects, including improved endothelial function, reduced inflammation, and increased tolerance to ischemia-reperfusion injury. In preclinical studies, increased ecto-5'-nucleotidase activity, the key enzyme in extracellular adenosine formation, plays an important role in these effects. Because human data are absent, we explored the effects of rosuvastatin on ecto-5'-nucleotidase activity and the clinical relevance of increased extracellular adenosine during ischemia in humans in vivo. The forearm vasodilator responses to 3 increasing periods of forearm ischemia (2, 5, and 13 minutes) were determined during placebo and caffeine (an adenosine receptor antagonist) infusion into the brachial artery. At the end of an 8-day treatment period with rosuvastatin (20 mg per day), this whole procedure was repeated. During both experiments, ecto-5'-nucleotidase activity was determined. Vasodilator responses are expressed as the percentage increase in forearm blood flow ratio from baseline. Rosuvastatin increased ecto-5'-nucleotidase activity by 49±17% and enhanced the vasodilator response after 2, 5, and 13 minutes of ischemia in the absence (146±19, 330±26, and 987±133 to 312±77, 566±107, and 1533±267) but not in the presence of caffeine (98±25, 264±54, and 727±111 versus 95±19, 205±34, and 530±62). Rosuvastatin increases extracellular formation of adenosine in humans in vivo probably by enhancing ecto-5'-nucleotidase activity. This action results in the improvement of reactive hyperemia and may further enhance the clinical benefit of statins, in particular in conditions of ischemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
722-7
pubmed:meshHeading
pubmed-meshheading:20679180-5'-Nucleotidase, pubmed-meshheading:20679180-Adenosine, pubmed-meshheading:20679180-Blood Flow Velocity, pubmed-meshheading:20679180-Brachial Artery, pubmed-meshheading:20679180-Caffeine, pubmed-meshheading:20679180-Central Nervous System Stimulants, pubmed-meshheading:20679180-Female, pubmed-meshheading:20679180-Fluorobenzenes, pubmed-meshheading:20679180-Forearm, pubmed-meshheading:20679180-Humans, pubmed-meshheading:20679180-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:20679180-Infusions, Intra-Arterial, pubmed-meshheading:20679180-Ischemia, pubmed-meshheading:20679180-Male, pubmed-meshheading:20679180-Pyrimidines, pubmed-meshheading:20679180-Sulfonamides, pubmed-meshheading:20679180-Time Factors, pubmed-meshheading:20679180-Up-Regulation, pubmed-meshheading:20679180-Vasodilator Agents, pubmed-meshheading:20679180-Young Adult
pubmed:year
2010
pubmed:articleTitle
Upregulation of ecto-5'-nucleotidase by rosuvastatin increases the vasodilator response to ischemia.
pubmed:affiliation
Departments of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
pubmed:publicationType
Journal Article, Controlled Clinical Trial, Research Support, Non-U.S. Gov't